<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Inflammatory arthritis and connective tissue disease  v2.0 MeG-CLS-041</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="inflammatory-arthritis-and-connective-tissue-disease">Inflammatory arthritis and connective tissue disease </h1>
<h2 id="executive-summary"><em>Executive summary</em> </h2>
<h2 id="introduction">Introduction </h2>
<p>Rheumatological disorders are difficult to diagnose accurately in our setting and can be difficult to treat, as we are limited by the poor availability of tests and treatments. They are also not common. Despite this, we are able to improve the quality of life and prognosis of most of the patients with the medications we have available.</p>
<p>Rheumatoid arthritis is the most common condition seen. It is a symmetric, inflammatory, peripheral polyarthritis. Untreated, it leads to joint destruction and disability.</p>
<p>Other connective tissue disorders are much less common. However, similar principles can be used to care for these patients.</p>
<h2 id="target-users">Target users </h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
</ul>
<h2 id="target-area-of-use">Target area of use </h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Outpatient department</p>
</div></li>
</ul>
<h2 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes </h2>
<p>This guideline outlines an approach to connective tissue and inflammatory conditions in our setting. It describes the use of methotrexate (the only available DMARD in our setting) and the clinical disease activity index for monitoring progress.</p>
<h2 id="limitations">Limitations </h2>
<p>We have no access to autoantibodies and other diagnostic tests. We cannot do CRP routinely.</p>
<p>We have limited access to drugs and no access to biologicals.</p>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<p>Rheumatoid arthritis presents with joint pain and swelling of the peripheral joints (affecting at least 3 joints), morning stiffness and difficulty performing activities of daily living (ADLs), all lasting at least 6 weeks. Other conditions such as psoriasis, inflammatory bowel disease, SLE should be absent. It is often gradual in onset, but may be intermittent at the beginning. Very occasionally, rheumatoid arthritis may present with a persistent monoarthritis. In these cases, septic arthritis, gout and other explanations must be excluded until a polyarthritis develops.</p>
<p>Extra-articular features of rheumatoid arthritis include anaemia, fatigue, pericarditis, rashes, eye complications, neuropathy, splenomegaly, Sjogren’s syndrome, vasculitis and others. Alternatively, these and other systemic features may reflect another connective tissue disorder.</p>
<h2 id="examination-findings">Examination findings</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Painful, tender, swollen joints – especially the proximal interphalangeal and metocarpophalangeal joints, the wrists, feet, elbows, shoulders, hip and knees.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Joint stiffness, pain on motion, limitation of motion</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Rheumatoid nodules</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Typical rheumatoid deformities may be seen in long-standing untreated cases.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>C-spine pain and stiffness, which may eventually lead to instability.</p>
</div></li>
</ul>
<p>Where an alternative diagnosis is suspected, examine carefully in all systems – paying particular attention to dermatological and musculoskeletal features.</p>
<h2 id="diagnostic-criteria">Diagnostic criteria</h2>
<p>For Rheumatoid Arthritis to be diagnosed, there should be any 4 of the following criteria present:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Morning stiffness for &gt; 1 hour each day</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Arthritis of three or more joints for &gt; 6 weeks</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Arthritis of hand joints</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Symmetric arthritis for &gt; 6 weeks</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Rheumatoid nodules</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Serum rheumatoid factor positive</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Radiographic changes typical of RA</p>
</div></li>
</ul>
<h2 id="investigations">Investigations</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Plain films of affected joints – may show osteopenia, joint space narrowing and bone erosions. However, they are not helpful if the diagnosis is clinically clear.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Rheumatoid factor – found in 70-80% of patients (and in 5-10 % of healthy people and 20-30 % of patients with other inflammatory conditions). Helpful, but not essential to the diagnosis.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>ESR – used for monitoring disease activity.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>FBC, U&amp;Es, LFTs and Hep B &amp; C screening – useful to establish baseline values for patients who will start methotrexate.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Other tests such as CK, U&amp;Es, HIV may be important in excluding alternative diagnoses.</p>
</div></li>
</ul>
<h3 id="further-investigation-where-diagnosis-unclear">Further investigation where diagnosis unclear </h3>
<p>Further investigations are not available in the Gambia. If patients are interested and able, there are many investigations available in Dakar and a referral should be made to Professor Pouye at Hôpital Le Dantec.</p>
<h2 id="management">Management </h2>
<p>Patients with probable rheumatoid arthritis and raised ESR should be started on disease modifying treatment (DMARD) as soon as possible.</p>
<p>All patients without contraindications should start on methotrexate.</p>
<p>Contraindications include:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Women who are pregnant or who want to be pregnant.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Patients with liver disease or excessive alcohol intake</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Patients with severe renal impairment (eGFR &lt; 30 ml/min)</p>
</div></li>
</ul>
<p>The presence of respiratory disease is a relative contraindication, so if there are respiratory symptoms, a chest X-ray is helpful to exclude TB or other relevant concerns.</p>
<h3 id="disease-modifying-treatment-dmard">Disease modifying treatment (DMARD) </h3>
<p>Start with <strong>methotrexate</strong> 7.5-15 mg once per week and titrate up as tolerated. Patients who are older, less heavy and with reduced renal function (eGFR &lt; 60 ml/min) should have the lower doses. Increase approximately every 4 weeks to a target dose of 15-25 mg once per week. If these doses are ineffective, the bioavailability can be increased without increasing gastrointestinal side effects by dividing the dose into 2 (taken on the same day once per week).</p>
<p>Patients on methotrexate should have FBC and LFTs checked once every 3 months. A chest X-ray should be done if there is any suggestion of respiratory symptoms.</p>
<p>Patients on methotrexate should take folic acid daily at a dose of 1 mg OD. As we have only 5 mg tablets, dosing once per week is adequate.</p>
<p>Methotrexate should be continued at an effective rate for 3-6 months after the disease enters remission. After this, the dose can be titrated down to the lowest effective level.</p>
<p>Combination DMARD treatment can be used for patients who continue to have high disease activity after 3-6 months of treatment with methotrexate. The methotrexate is continued and <strong>sulfasalazine</strong> and <strong>hydroxychloroquine</strong> are added. Sulfasalazine and hydroxychloroquine can also be used in combination for patients that cannot take methotrexate.</p>
<p>Sulfasalazine is started at 500 mg BD and increased by 500 mg each week to a dose of 1500 mg BD.</p>
<p>Hydroxychloroquine is given at a dose of 400 mg OD (maximum of 5 mg/kg/day).</p>
<h3 id="symptomatic-treatment">Symptomatic treatment </h3>
<p>NSAIDS rapidly reduce inflammation and provide pain relief. They should be used for all patients with active disease at maximal anti-inflammatory doses for at least 2 weeks before being withdrawn gradually. Use <strong>ibuprofen</strong> 800 mg QDS (ibuprofen is more effective and has fewer gastric side effects than diclofenac). Consider also given omeprazole 20 mg OD for patients who also receive steroid treatment.</p>
<p>Steroids can be used to rapidly control disease in patients with more severe disease or in patients for whom NSAID treatment is ineffective. Give <strong>prednisolone</strong> 20 mg OD for 1 month. Reduce the dose gradually to a maintenance level of 5-10 mg OD once symptoms settle and wean off completely within 4 months, as successful DMARD therapy is usually seen within 4 to 6 months. Lower doses of glucocorticoid are usually adequate when combined with effective DMARDs.</p>
<p>These treatments can be repeated as necessary for patients experiencing flares of their disease.</p>
<h3 id="monitoring-disease-activity">Monitoring disease activity </h3>
<p>Various scores are available for monitoring disease activity in rheumatoid arthritis. The Clinical Disease Activity Indicator (CDAI) is simple to calculate and is suitable for our setting.</p>
<p>28 joints are reviewed – 10 proximal interphalangeal joints, 10 metocarpophalangeal joints, 2 wrists, 2 elbows, 2 shoulders and 2 knees. Each should be examined for swelling and tenderness. Estimate out of 10 (where 0 is completely well and 10 is as ill as possible) how ill you think the patient is. Ask the patient the same question.</p>
<p>Now add the number of swollen joints, the number of tender joints, your assessment and the patient’s assessment. This gives a score out of 76.</p>
<table>
<thead>
<tr class="header">
<th><strong>Activity level</strong></th>
<th><strong>CDAI score</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Remission</td>
<td>&lt; 2.8</td>
</tr>
<tr class="even">
<td>Low disease activity</td>
<td>3-10</td>
</tr>
<tr class="odd">
<td>Moderate disease activity</td>
<td>11-22</td>
</tr>
<tr class="even">
<td>High disease activity</td>
<td>&gt; 22</td>
</tr>
</tbody>
</table>
<h2 id="non-pharmacologic-treatment">Non-pharmacologic treatment</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Patient education regarding the illness, treatment and prognosis.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Heat and cold therapies: Heat is an effective modality for the relief of joint pain and stiffness caused by RA. Cold is preferable for treatment of an acutely inflamed joint.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Orthotics and splints</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Therapeutic exercise: Patients with well-controlled RA should be encouraged to engage in 30 minutes of daily aerobic exercise several times a week. Hand exercises may also be useful.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Joint-protection education e.g. maintenance of good posture, avoidance of overuse during inflammation, modification of tasks to decrease joint stress</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nutritional and dietary counselling</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Interventions to reduce risks of cardiovascular disease, including smoking cessation and lipid control</p>
</div></li>
</ul>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care </h2>
<p>Patients with inflammatory arthritis should be seen by a doctor whenever possible, given how uncommon it is in the Gambia.</p>
<p><strong>References</strong></p>
<p>Ally, Meyer and Anderson (2016). Early rheumatoid arthritis: focus on RA in the developing world. South African Family Practice 2016; 58(4):164-166.</p>
<div data-custom-style="EndNote Bibliography">
<p>Medscape (2020) Rheumatoid arthritis (RA). <a href="https://emedicine.medscape.com/article/331715-overview"><span data-custom-style="Hyperlink">https://emedicine.medscape.com/article/331715-overview</span></a> Accessed 28 June 2020.</p>
</div>
<div data-custom-style="EndNote Bibliography">
<p>NICE Guideline (2018) Rheumatoid arthritis in adults: management. <a href="https://www.nice.org.uk/guidance/ng100/chapter/Recommendations%20Accessed%2028%20June%202020"><span data-custom-style="Hyperlink">https://www.nice.org.uk/guidance/ng100/chapter/Recommendations Accessed 28 June 2020</span></a>.</p>
</div>
<p>Singh et al (2016). 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care and Research 2016; 68(1):1-25.</p>
<div data-custom-style="EndNote Bibliography">
<p>Smolen and Aletaha (2018). Assessment of rheumatoid arthritis activity in clinical trials and clinical practice. Up To Date.</p>
</div>
<div data-custom-style="EndNote Bibliography">
<p>UpToDate (2020) Initial treatment of rheumatoid arthritis in adults. <a href="https://www.uptodate.com/contents/initial-treatment-of-rheumatoid-arthritis-in-adults?csi=6bb16911-2bca-40f9-987c-cc27a347a127&amp;source=contentShare#H2985885"><span data-custom-style="Hyperlink">https://www.uptodate.com/contents/initial-treatment-of-rheumatoid-arthritis-in-adults?csi=6bb16911-2bca-40f9-987c-cc27a347a127&amp;source=contentShare#H2985885</span></a> Accessed 28 June 2020.</p>
</div>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Karen Forrest</th>
<th>Date: 22 May 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Fatai Akemokwe</td>
<td>Date: 17 June 2018</td>
</tr>
<tr class="even">
<td><strong>Reviewed by</strong></td>
<td>Name Musa Jallow</td>
<td>Date 28 June 2020</td>
</tr>
<tr class="odd">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="even">
<td>1.0</td>
<td>New document</td>
<td>15 August 2020</td>
</tr>
<tr class="odd">
<td>1.1</td>
<td>Executive summary added</td>
<td>15 August 2020</td>
</tr>
<tr class="even">
<td>2.0</td>
<td>Diagnostic criteria added, Examination findings updated, , non-pharmacologic treatment added, new reference added</td>
<td>01 November 2020</td>
</tr>
<tr class="odd">
<td><p>Review Comments</p>
<p>(<em>if applicable)</em></p></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
